Invasive Group A Streptococcal Infections, Israel by Moses, Allon E. et al.
Emerging Infectious Diseases  •  Vol. 8, No. 4, April 2002 421
RESEARCH
Invasive Group A Streptococcal 
Infections, Israel
Allon E. Moses,* Sara Goldberg,† Zinaida Korenman,‡ Miriam Ravins,† 
Emanuel Hanski,† Mervyn Shapiro,* and the Israeli Group for the Study of Infections 
Caused by Streptococcus pyogenes1
We conducted a prospective, nationwide, population-based study of invasive group A streptococcal infec-
tions in Israel. We identified 409 patients (median age 27 years; range <1-92), for an annual incidence of
3.7/100,000 (11/100,000 in Jerusalem). The mortality rate was 5%. Bacteremia occurred in 125 cases
(31%). The most common illnesses were soft-tissue infection (63%) and primary bacteremia (14%). Thirty
percent of patients had no identifiable risk factors for infection. Eighty-seven percent of pharyngeal carriers
had the same serotype as the index patient. M types included M3 (25%), M28 (10%), and M-nontypable
(33%). A marked paucity of M1 serotype (1.2%) was detected. The results highlighted concentrated pock-
ets of invasive disease in the Jewish orthodox community (annual incidence 16/100,000). 
roup A streptococcus (GAS) causes human disease rang-
ing from noninvasive infections such as pharyngitis or
impetigo to life-threatening conditions such as bacteremia,
necrotizing fasciitis (NF), and toxic-shock syndrome (TSS).
Invasive GAS infections are thought to result from entry of
bacteria through the skin, although often the site of entry can-
not be determined. Since the mid-1980s, retrospective reviews
of invasive GAS disease in different geographic areas have
described an increase in deaths from these infections (1-4).
These studies have also emphasized the changing nature of the
population affected and have shown that young, healthy per-
sons often have severe infections (4,5). This increased severity
of invasive GAS infections has produced an augmented search
for new virulence factors and host determinants that may
amplify the potential of this organism for producing disease.
Since GAS vaccines are being developed by several groups
(6,7), baseline incidence data on severe GAS infections are
needed. Information regarding the geographic distribution of
M types will assist in directing vaccine development to preva-
lent strains. Prospective population-based studies provide an
assessment of the true incidence of severe infection and are
thus the preferred method for studying the epidemiology of
disease. Few such studies of severe GAS infections have been
performed (5,8-11); no previous studies have encompassed the
epidemiology of an entire country.
We report the clinical characteristics of patients and bacte-
rial attributes of GAS isolates from a 2-year, nationwide, pro-
spective, population-based study to determine the incidence of
invasive GAS diseases in Israel. In the greater Jerusalem area,
we conducted an in-depth study to determine the prevalence of
carriage of GAS in household contacts of index patients with
invasive disease.
Methods
We studied invasive GAS infections in Israel from January
1997 through December 1998. Collaboration between the
study center in Jerusalem and 24 of the 25 acute-care hospitals
in Israel was coordinated with the infectious diseases consult-
ant or the director of the microbiology laboratory at each hos-
pital. These hospitals serve approximately 95% of the Israeli
population. 
We provided each hospital with kits for transporting bacte-
rial isolates and a questionnaire requesting the following
demographic and clinical data for each case: age, sex, infec-
tion site, presence of hypotension, and signs of organ damage,
including renal failure, adult respiratory distress syndrome,
disseminated intravascular coagulation, or mental changes.
In a 1995 census from the Israeli Central Bureau of Statis-
tics, the population of Israel was 5,548,000; 81% were Jews.
Of the total population, 698,000 were children ≤5 years of age,
990,000 were 6-15 years of age, 2,550,000 were 16-45 years
old, and 1,310,000 were persons >45 years of age. The median
age of the population in Israel was 27.4 years (23.2 in the
greater Jerusalem area). 
In the greater Jerusalem area, the total population was
602,100; 421,200 were Jews, and 180,900 were Arabs. Among
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the Jewish population, 120,000 were Orthodox Jews, with an
average of 5.5 members per family, compared with 2.9 in the
nonorthodox Jewish population. Using age-adjusted rates for
Human herpesvirus 3 (HHV-3) infection (12), we estimated
that 4,100 cases of varicella occurred annually in children <10
years of age in the Jerusalem cohort.
Invasive disease was defined as the isolation of GAS from
a normally sterile site such as blood, joint, or wound infection
or from deep tissue retrieved during surgery. Isolates from the
throat, ear, and eye were excluded. TSS was defined according
to conventional criteria (13).
A study nurse (S.G) interviewed household contacts
(defined as persons who lived in the same household as the
index patient) within 3 days of obtaining a positive culture
from an index patient who had been admitted to a hospital (one
of three medical centers) serving the greater Jerusalem area.
Information was obtained about antibiotic treatment and the
presence of a recent throat or skin infection. Pharyngeal cul-
tures were obtained from all household contacts.
Hospital laboratories identified the isolate as GAS by
using a commercial latex agglutination kit. We sent all isolates
to the Israel Ministry of Health Streptococcal Reference Labo-
ratory for M- and T-typing and confirmatory GAS antigen typ-
ing. The presence of the genes encoding the two exotoxins A
and C (speA, speC) was assessed by polymerase chain reac-
tion (PCR) (14).
Statistical analysis was done by using the chi-square test
for differences in proportions. A p value of <0.05 was
regarded as significant.
Results
Clinical and Epidemiologic Characteristics
During the 2-year study period, 24 medical centers in
Israel submitted 423 specimens. Of these, 14 isolates were not
included in the study: 6 were found not to be GAS, and 8 were
isolates from an eye or ear infection. Thus, 409 isolates were
available for further study. The audit of case reporting showed
a sensitivity that ranged from 30% to 70% among different
institutions. However, for patients with bacteremia the average
sensitivity of case reporting was 75%. 
The annual incidence of invasive GAS infection in Israel
was 3.7 per 100,000 population (Table 1). The median age was
27 years (range 1 week to 92 years). Incidence was highest in
children <5 years and adults >45 years of age (Table 1). For
bacteremia and TSS, the annual incidences in the national
cohort (Table 1) were 1.1/100,000 and 0.25/100,000, respec-
tively, with the highest incidence in persons ≥45 years of age
(p<0.001). The case-fatality rate of the national cohort could
not be assessed because deaths were underreported.
The disease entities associated with invasive GAS infec-
tion are summarized in Table 2. Of the 409 cases, 125 (31%)
had bacteremia, which was considered to be primary (14%) if
no source of infection was identified. The median age of bac-
teremic patients was 48 years, considerably higher than the
median age (27 years, p<0.001) of all participants. Of 42 cases
with cellulitis, 59% also had bacteremia. Of 14 cases of necro-
tizing fasciitis, 4 were bacteremic, and GAS was isolated from
deep fascia in 10 others. Fourteen patients had pneumonia: in
5 patients GAS was isolated from blood, in 2 from pleural
fluid, in 1 from lung tissue, and in the other 6 from sputum. Of
10 patients with burns, 7 were from one burn unit. Three of
these seven comprised a single nosocomial outbreak.
In the national cohort, of 28 cases defined as TSS, 16
(57%) were male. In 20 (71%) of the TSS patients, GAS was
isolated from blood cultures; in 10 this bacteremia was pri-
mary. Six had concurrent NF, two were children with chicken-
pox, and two had cellulitis. Only one patient was known to be
positive for HIV infection.
Characteristics of Bacterial Isolates 
Serologic typing was performed for 401 isolates (98%). Of
these, 33% were M-nontypable. The typable strains belonged
to 23 different M serotypes. The most common strain was M3,
constituting 25% of all isolates. The next most common sero-
types were M28 (10%), M2 (5%), M62 (4%), M41 (3%), and
M12 (3%). M1 was isolated from only five cases (1.2%). Four
isolates gave a positive serologic reaction with two M serotypes. 
Among the M-nontypable isolates, 21 different T serotypes
were identified (data not shown). The most prevalent were
T28 (11%), T12 (9%), T11 (8%), and T3/13/B3264 (8%); 28%
were T-nontypable. T serotypes were different from those
Table 1. The incidence of diseases from the national cohort, the Jerusalem cohort, the cohort of patients with bloodstream isolates, and the toxic-
shock syndrome cohort, by age group, 1997–1998
Age group  
(years)
National cohort:  
no. of patients
Annual 
incidencea
Jerusalem: no. 
of patients
Annual 
incidence
Bacteremia: 
no. of patients
Annual 
incidence
TSS: no. of 
patients
Annual 
incidence
<5 88 6.3 38 19 26 1.86 5 0.36
6-15 53 2.68 16 6.8 11 0.56
16-45 116 2.27 41 8 24 0.47 8 0.16
>45 109 4.16 38 15 62 2.37 15 0.57
Unknown 43 2
Total 409 3.69 133 11 125 1.13 28 0.25
Median age (yr) 27 24 48 49
aAnnual incidence = cases per 100,000 population. TSS = Toxic-shock syndrome.Emerging Infectious Diseases  •  Vol. 8, No. 4, April 2002 423
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usually associated with M1. The M serotype distribution was
similar in the national and Jerusalem cohorts.
Four hundred and one isolates were tested for the presence
of speA or speC by PCR. Ten percent were positive for speA
in both cohorts. Thirty-two percent and 37% were positive for
speC in the national and Jerusalem cohorts, respectively. Of
the 101 M3 strains, 21% were positive for speA. 
Jerusalem Cohort
Of 409 patients who could be evaluated, 133 were from the
Jerusalem area. In Jerusalem, the audit of case reporting
showed a sensitivity of 94%. The median age was 24 years.
The annual incidence of disease was 11/100,000 (Table 1). In
this cohort the highest annual incidence was in the orthodox
Jewish community (16/100,000; Table 3). The incidence dif-
fered by age group, with the groups <5 years (19/100,000) and
>45 years (15/100,000) having the highest incidence (p <
0.01). Males accounted for 65%. In the Jerusalem group there
were 86% Jews and 14% Arabs (Table 3).
The overall case-fatality rate in the Jerusalem area was 5%
(7/133) but was 14% (6/44) among patients with bacteremia.
Four of the seven patients who died in Jerusalem were >65
years of age.
All five cases of chickenpox-related GAS infection were in
the Jerusalem cohort, for an estimated attack rate of 61/
100,000 cases per year. One child died of the infection. All
were children <4 years of age from orthodox Jewish families,
but no epidemiologic association could be demonstrated since
strains belonged to a variety of M serotypes.
In the Jerusalem cohort of 133 cases, we assessed the pres-
ence of underlying medical conditions that may predispose to
GAS infection. Forty patients (30%) had no underlying
disease. Nineteen percent had an acutely infected skin lesion.
Twelve percent had a chronic skin condition, which was
acutely infected with GAS. Ten percent of patients had diabe-
tes mellitus, and nine percent had various forms of cancer.
Nine pregnant women (7%) were infected before or shortly
after delivery. Five children had chickenpox. 
In the Jerusalem cohort, pharyngeal cultures were obtained
from 302 contacts of 60 index patients. Relatives of 73 index
patients were not studied because of lack of informed consent
(22), nonavailability due to early discharge (19), or absence of
family contacts (32). The mean number of family contacts per
index patient was 5 (range 1-9). Twenty-eight index patients
were associated with 61 household carriers of GAS, 75% of
whom were ≤15 years old. Only one contact (a child with
pharyngitis) was symptomatic. The gender distribution of the
carrier cohort was similar to that of the general population.
Comparison of the M serotypes of the carriers and their
respective index patients disclosed identity in 87% of cases.
Discussion
Our prospective population-based study is a first nation-
wide survey of the incidence of invasive GAS. The annual
incidence of invasive GAS infections in Israel (3.7/100,000) is
similar to that reported from Pima County, Arizona (4), and
Atlanta, Georgia (9), but is considerably higher than that
reported for Ontario, Canada (1.5/100,000) (8). The annual
incidence in the Jerusalem cohort was three times higher (11/
100,000) than that of the national cohort, reflecting, at least in
part, a greater accuracy of reporting, achieved by frequent con-
tact of the study nurse with the three medical centers. The rela-
tively large number of orthodox Jews living in the Jerusalem
area may also have contributed to the higher incidence of
infection in this city. Unlike Ontario or Connecticut (8,11),
reporting invasive GAS infections in Israel is not mandatory,
contributing to the relatively low reporting accuracy. Thus, the
true incidence of invasive GAS disease in Israel may be closer
to that of the Jerusalem cohort, which is substantially higher
than that reported by other population-based studies. We made
routine telephone calls to the hospital contacts to encourage
participation and confirm that cases were being reported.
Audits of one third of the large and small hospital laboratories
were conducted twice during the study period to evaluate the
proportion of cases actually reported. Since some of the Arab
Table 2. Clinical characteristics of invasive GAS infections: compari-
son of the national cohort to the Jerusalem cohort, 1997–1998
Disease National cohort % Jerusalem cohort %
Soft tissue infectiona 272 67 88 66
Primary bacteremia 57 14 11 8.3
Pneumonia 14 3.4 4 3
Postpartum 10 2.4 6 4.5
Arthritis 8 2 1 < 1%
Lymphadenitis 6 1.5 2 1.5
Chickenpox 5 1.2 5 3.8
Meningitis 5 1.2 2 1.5
Peritonitis 5 1.2 4 3
PID 5 1.2 1 < 1%
Osteomyelitis 4 < 1% 2 1.5
Others 14 3.4 5 3.8
Unknown 4 < 1%
Total 409 100 133 100
aSoft tissue infection includes 35 patients with abscesses, 14 with necrotizing fasciitis, 
and 10 with burns. PID = pelvic inflammatory disease.
Table 3. Religious distribution of patients in the Jerusalem cohort, 
1997–1998 
Religiona
Number 
(n=133) % Annual incidenceb
Jewish 113 85 13
Orthodox Jewish 39/113 26 16
Moslem/Christian 
Arabs
18 14 5
Other 2 1
aThe Orthodox Jewish cohort is included in the Jewish cohort.
bAnnual incidence = cases per 100,000 population.RESEARCH
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population in Jerusalem uses the East Jerusalem Arab hospi-
tals, which were not included in the study, infections occurring
in a small proportion of Jerusalem Arab patients may have
been missed.
Risk factors for GAS infection were not studied in the
national cohort. In the Jerusalem cohort, 30% were previously
healthy patients without evident risk factors. This finding is
consistent with those of other studies, supporting the notion
that underlying illnesses appear to play an important role in the
occurrence of invasive GAS disease (4,8,9,15-17). Previous
skin lesions, diabetes mellitus, and cancer were the most com-
mon conditions predisposing to GAS infection. Alcoholism
and AIDS are relatively rare in Israel (18) and were not found
to be risk factors for our patients.
In Israel the incidence of invasive streptococcal disease in
children was higher than reported previously (9), consistent
with our earlier finding that children with GAS bacteremia in
Jerusalem were younger than those reported by others (19). In
Jerusalem the incidence of GAS infection in the <5-year age
group was higher than previously reported (19/100,000). This
incidence remained elevated (14/100,000) even after five cases
of an infection secondary to chickenpox were excluded from
analysis. 
In Jerusalem, 40% of children (≤15 years of age) with
invasive GAS infections were from the orthodox Jewish com-
munity. The overall incidence for this group was 16/100,000
population and was probably even higher in children ≤15 years
of age, although data for age distribution were not available
for this group. In this community, families are large and the
relatively crowded living conditions may facilitate the spread
of streptococci (20). Recently, a higher pharyngeal carriage
rate (odds ratio 5.0; 95% confidence interval 2.1-11.9) of GAS
was reported for an orthodox Jewish community in London
(21). In Jerusalem, the incidence of GAS infection was also
much higher in the group >45 years of age (Table 1). Thus, the
incidence of severe GAS infections reported in the Jerusalem
area is much higher than previously reported. The mortality
rate (5%) in the Jerusalem cohort was lower than that reported
by Davies et al. (8) and Zurawski et al. (9) but is similar to the
rate reported for bacteremic patients at the Hadassah Medical
Center in Jerusalem (22).
Both bacteremia and TSS occurred at a significantly older
age (P<0.0001) (median age 48 and 49 years, respectively) than
the median age of the general population in Israel (Table 1).
The annual rate of TSS in our study was similar to that reported
by Davies et al. (0.2/100,000), who also found that severe dis-
ease occurred preferentially in older patients. NF was relatively
rare in Israel (annual incidence 0.1/100,000), accounting for
3.4% of all patients and 4.5% of the Jerusalem cohort patients.
This was similar to the percentage reported by Zurawski (3%)
but considerably less than that reported by Davies et al. (13%).
Zurawski et al. (9) suggested that the low incidence of NF
might have been due to ascertainment bias, engendered by the
laboratory-based study methods, which may have missed cases
of NF without concomitant bacteremia. However, in Jerusalem
the close association between the study team and their clinical
and laboratory counterparts in all three medical centers makes
such an ascertainment bias unlikely. The differences between
population-based studies may be due to microbiologic
attributes of the strains involved or other unknown factors.
Nosocomially acquired invasive streptococcal infections
were relatively rare. Postpartum infections accounted for 2.4%
and 4.5% of the national and Jerusalem cohorts, respectively.
Although this infection can be hospital acquired (22, 23), GAS
may also arise from the patient’s own bacterial flora (8). Seven
of the 10 burn-related infections occurred in one hospital, and
three cases belonged to a single serotype (M3, speC+). Such
an outbreak has been reported to occur by transfer of GAS
from medical personnel to patients (24-29).
Our data support the assumption that chickenpox is a risk
factor for invasive GAS disease (8,9,30-33). In our cohort, all
children with chickenpox were from orthodox Jewish families.
Nevertheless, cases were caused by diverse M serotypes and
occurred in several different city neighborhoods without any
epidemiologic link between them.
The most striking microbiologic characteristic of the GAS
isolates of both the national and Jerusalem cohorts is the pau-
city of the M1 serotype. This finding contrasts with many pre-
vious reports, which described the M1 serotype as the
prominent isolate from patients with invasive GAS infection,
particularly those with NF or TSS (34-40). Our M-nontypable
strains had 21 distinct T serotypes that differed from those usu-
ally associated with M1 strains. Thus, emm typing would be
unlikely to categorize these nontypable isolates as M type 1.
The association between M1 and the production of exo-
toxin A is well established (37) but not universal (41). The
prevalence of speA in our cohort (10%) was lower than that
found by Zurawski (34%) (9) and Kiska, who observed that
98% of M1 and M3 outbreak strains were speA positive (5).
Half our speA-positive cases were serotype M3, but few were
associated with TSS and NF. We concur with Davies (8) that
factors other than speA play a role in TSS pathogenesis. These
findings and the paucity of the M1 serotype among our isolates
suggest that no single invasive clone is responsible for severe
disease (20) and that strains attain their virulence through
means other than speA. The relative prevalence of speC in our
study was similar to that found by others (8).
Serotype M3, the most frequent M type in our cohort and a
relatively common isolate in other studies of invasive GAS
(41,42), seems to have replaced M1 as the leading cause of
invasive streptococcal disease (8). In a retrospective analysis
of GAS bacteremia in Jerusalem over a 6-year period (1987-
1992), none of the 41 isolates available were serotype M3, 11
(27%) were nontypable, 4 were M12, and 2 were M1 (22).
Thus, an unexplained increase in the rate of invasive M3
strains in Jerusalem has occurred. Nevertheless, this increase
has not been accompanied by a change in the absolute number
of bacteremic streptococcal cases per year, and the mortality
rate has remained constant. Therefore, we cannot conclude
that infections with M3 result in more cases of bacteremia orEmerging Infectious Diseases  •  Vol. 8, No. 4, April 2002 425
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are more virulent. Only 20% of our M3 strains harbored the
speA gene, compared with 100% of the strains from Japan
(41). In Israel, 67% of 21,517 GAS isolates (mostly from pha-
ryngeal swabs taken over a 10-year period) were M-non-
typable, and 99% were T-typable (43). The most prevalent M
serotypes were M12 (17%) and M1 (6%), and the most preva-
lent T type was 3/13/B3264 (20%). Ten years later, Yagupsky
et al. found 90% strains (10/13 cases) of GAS isolated from
children with bacteremia to be M-nontypable (44).
The M28 serotype, accounting for 10% of our cases, was
reported to be a common serotype in invasive GAS diseases by
some investigators (8) but not by others (9). We also had a rel-
atively high percentage of M-nontypable isolates. This finding
is in contrast to those who have been able to serologically type
>90% of isolates (41) but is similar to findings of surveys in
which 60% or 80% of isolates were nontypable (9,45). emm-
typing (46) may clarify the actual M type of those strains.
In the Jerusalem cohort, we found a particularly high prev-
alence of patients with family members who had GAS in their
pharynx. As reported previously (47), the M types of almost
all isolates (87%) from household contacts were identical to
those found in the index patients. We chose to administer pre-
ventive antimicrobial therapy to positive contacts, although
this practice is still controversial (48). None of the contacts
had invasive disease. 
As in other studies (47), we found that asymptomatic carri-
ers were mostly young children. Whether the index patients
were infected from an asymptomatic carrier or vice versa is
impossible to determine. The reasons for one person remain-
ing an asymptomatic carrier while another has a severe, some-
times lethal infection have not been clarified. Whether there
are any genetic differences between the index patient/contact
pair of bacterial isolates or whether varying virulence genes of
GAS are expressed under different clinical conditions remains
to be determined. Further studies of GAS epidemiology and
pathogenesis are required to determine the reasons for acquir-
ing severe invasive GAS diseases in specific hosts. This
knowledge will allow a more accurate definition of the risk
factors for these infections and may lead to development of
effective intervention strategies.
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